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Purpose of the study
Today, use of antiretroviral (ARV) therapy in patients with
AIDS is associated with longer survival [1]. However, sev-
eral new complications have been described in the last few
years, mainly cardiovascular events. Several abnormalities
have been related to cardiovascular complications:
endothelial dysfunction, dyslipidemia, insulin resistance,
or prothrombotic state. However, none of these entities
totally explain cardiovascular complications. The aim of
this research was to determine the frequency of SPS asso-
ciated with ARV therapy.
Methods
We performed a cross-sectional study of patients with
AIDS who received ARV for at least 6 months. We studied
two groups of patients depending on the use of protease
inhibitors. SPS was evaluated with a functional assay
according to the recommendations described in the liter-
ature [2]. Results are expressed as % of platelet aggregom-
etry. Characteristics of the patients are expressed as
median and ranges. We used a X2 test to determine if there
were differences between the groups in terms of frequency
of SPS.
Summary of results
We studied 100 patients with AIDS: four women and 96
men. For the whole group, mean age was 45 yrs (range 22
to 77). Mean time of treatment with ARV drugs was 90
months (range 8 to 177). We found that 73% of the
patients had criteria to be considered carriers of SPS. Sixty-
nine percent of the patients had type 2 SPS (only with
epinephrine), 27% had type 1 SPS (with epinephrine and
ADP), and only 4% of the patients had type 3 SPS (with
ADP). The analysis of results according to the group of
study showed that 54.8% of patients with SPS were receiv-
ing protease inhibitors (p = 0.239).
Conclusion
SPS was recently described as a relatively frequent cause of
either venous or arterial thrombotic events. To date, no
single cause of thrombophilia can explain the growing
incidence of vascular events associated to ARV in patients
with AIDS. A few years ago, our group informed a large
series of venous thromboembolic events in patients with
AIDS in which none of the thrombophilic causes
described in the general population was found signifi-
cantly. Therefore, we attempted to investigate other causes
of thrombophilia that may be affecting patients with
AIDS. We have found that SPS is a very frequent condition
in patients with AIDS receiving ARV therapy for at least 6
months. Moreover, we found that protease inhibitors are
not associated with the appearance of the syndrome in
this population. A controlled study about this association
is warranted.
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